Neptune Technologies & Bioressources Inc. Announces Major Breakthrough in the Omega-3 Market
September 29 2010 - 8:30AM
Neptune Technologies & Bioressources Inc. ("Neptune")
(Nasdaq:NEPT) (TSX-V:NTB) is proud to announce that after two years
of rigorous review of NKO® safety and clinical research data, the
Canadian Minister of Health has approved exclusively for NKO®
therapeutic and risk reduction claims, corroborating aspects of
Neptune's clinical research and substantiating NKO® safety and
effectiveness on certain prevalent chronic diseases.
"Health claims are becoming among the most important drivers
influencing the purchasing of Omega-3 supplements worldwide. With
this outstanding achievement, Neptune reinforces its Leader
position as a golden standard in the krill oil market," said Andre
Godin, CFO.
Substantial preclinical and clinical evidence reviewed by Health
Canada relating to the safety and effectiveness of NKO® lead to the
approval of the following fundamentally competitive health
claims:
1. Cardiovascular health: |
a. Helps to reduce
the levels of LDL cholesterol (in conjunction
with |
conventional statin therapy): 2 softgels
(1g) per day |
b. Helps to
increase the levels of HDL
cholesterol (in conjunction with |
conventional statin therapy): 2 softgels
(1g) per day |
c. Helps to reduce
the levels of triglycerides (in conjunction
with |
conventional statin therapy): 4 softgels
(2g) per day |
|
2. Inflammation |
a. Helps to reduce
C-reactive protein levels, a clinical marker |
of inflammation:
1 softgel (0.5g) per day |
b. Helps to reduce
pain associated with osteoarthritis: 1
softgel |
(0.5g) per day |
|
3. Women's Health: |
a. Helps to relieve
symptoms of premenstrual syndrome
(PMS): |
4 softgels (2g) per day |
b. Helps to relieve
symptoms of dysmenorrhea: 4 softgels (2g) |
per day |
The Health Canada health claim review process is considered one
of the most rigorous worldwide, recognized as a model among certain
global regulatory authorities. The review process involves an
extensive assessment of the accuracy, validity and evidence
supporting the proposed clinically proven health claims. "The Food
and Drugs Act, which regulates health claims, requires that the
health claims be scientifically supported and not misleading," said
Dr. Wael Massrieh, Ph.D. Medicine, Director of
R & D. "In June 2009 Health Canada approved health
claims for omega-3, among the strongest of which was the claim that
products providing 1g - 3g EPA + DHA, per day (amounting to 3-10g
of fish oil per day, or 6-20 softgels) help to reduce serum
triglycerides, compared to 4 NKO® softgels recently approved
for the same indication. Contrary to fish oil, Health Canada
approved a stronger claim for NKO® for cholesterol with a decrease
of LDL (bad cholesterol) and increase of HDL (good cholesterol)
using only two softgels per day as well as an anti-inflammatory
claim using only one softgel per day and a specific claim for
premenstrual syndrome (PMS)," he added.
"The NKO® approved claims are competitive when compared to the
already approved claims for fish oils since not only have they been
accepted at significantly much lower doses, but they also offer
more specific health benefits in cardiovascular, joint and women
health," said Andre Godin, CFO. "This strategic milestone is
expected to have a positive effect on sales because it fulfills new
consumer requirements," he added. A list of the approved claims can
be found on www.MyNKO.com.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma is developing a product portfolio of proprietary
novel long-chain omega-3 phospholipids. Phospholipids are the
major component of cell membranes and are essential for all vital
cell processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by potent antioxidants. Acasti Pharma is focusing initially on
treatments for chronic cardiovascular conditions within the
over-the-counter, medical food and prescription drug markets.
About NeuroBioPharm
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither NASDAQ nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking statements"
within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Technologies & Bioressources Inc.
Andre Godin, V.P. Administration and Finance
+1 450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
Acasti Pharma Inc.
Dr. Tina Sampalis, President
+1 450.686.4555
t.sampalis@acastipharma.com
www.acastipharma.com
CEOcast
Jim Fallon
+1 212-732-4300
jfallon@ceocast.com
www.ceocast.com
Howard Group
Grant Howard
(888) 221-0915
grant@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024